Pneumococcal conjugate vaccination for older adults: Reply letter to Hollingsworth et al.

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 1, 2014, Pages 47-51

  Fedson, David S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ANTIBODY RESPONSE; BACTERIAL PNEUMONIA; CLINICAL EFFECTIVENESS; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IMMUNOGENICITY; LETTER; MORTALITY; NON BACTEREMIC PNEUMOCOCCAL PNEUMONIA; NON BACTEREMIC PNEUMONIA; PNEUMOCOCCAL INFECTION; VACCINATION;

EID: 84894433478     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26422     Document Type: Letter

References (25)

1. Hollingsworth R, Isturiz R. Pneumococcal conjugate vaccination of older adults: Conjugate or polysaccharide? Hum Vaccin Immunother 2013; 10; In press; PMID:24018552.
2. Fedson DS, Guppy MJ. Pneumococcal vaccination of older adults: conjugate or polysaccharide? Hum Vaccin Immunother 2013; 9:1382-4; PMID:23732892; http://dx.doi.org/10.4161/hv.24692
3. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180:48-58; PMID:19124790; http://dx.doi.org/10.1503/cmaj.080734
4. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013; 1:CD000422; PMID:23440780
5. Fedson DS, Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004; 22:927-46; PMID:15161070; http://dx.doi.org/10. 1016/j.vaccine.2003.09.027
6. Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, Samson SI. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines 2011; 10:1143-67; PMID:21810065; http://dx.doi.org/10.1586/erv.11.99
7. Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, Pebody R, Miller E. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009; 49:1318-25; PMID:19814624; http://dx.doi.org/10.1086/606046
8. Musher DM, Sampath R, Rodriguez-Barradas MC. The potential role for protein-conjugate pneumococcal vaccine in adults: what is the supporting evidence? Clin Infect Dis 2011; 52:633-40; PMID:21292668; http://dx.doi.org/10. 1093/cid/ciq207
9. Grabenstein JD, Manoff SB. Pneumococcal vaccines in adults: assessing the evolving evidence. Vaccine 2011; 29:6149-54; PMID:21763386; http://dx.doi.org/10.1016/j.vaccine.2011.06.116
10. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41; PMID:19947881; http://dx.doi.org/10.1086/648593
11. Guevara M, Barricarte A, Gil-Setas A, García-Irure JJ, Beristain X, Torroba L, Petit A, Polo Vigas ME, Aguinaga A, Castilla J. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect 2009; 15:1013-9; PMID:19673968; http://dx.doi.org/10.1111/j.1469-0691.2009.02904.x
12. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009; 49:205-12; PMID:19508165; http://dx.doi.org/10.1086/599827
13. Miller E, Andrews NJ, Waight PA, Slack MPE, George RC. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011; 11:760-8; PMID:21621466; http://dx.doi.org/10.1016/S1473-3099(11) 70090-1
14. Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio 2011; 2:e00309-10; PMID:21264063; http://dx.doi.org/10.1128/mBio.00309-10
15. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med 2013; 369:155-63; PMID:23841730; http://dx.doi.org/10.1056/ NEJMoa1209165
16. Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine 2012; 30:5437-44; PMID:22728289; http://dx.doi.org/10.1016/j.vaccine.2012.05.076
17. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Lee BY, Zimmerman RK. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults. Am J Prev Med 2013; 44:373-81; PMID:23498103; http://dx.doi.org/10.1016/j.amepre.2012.11.035
18. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012; 307:804-12; PMID:22357831; http://dx.doi.org/10.1001/jama.2012.169
19. Musher DM, Manoff SB, McFetridge RD, Liss CL, Marchese RD, Raab J, Rueda AM, Walker ML, Hoover PA. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum Vaccin 2011; 7:919-28; PMID:21860256; http://dx.doi.org/10.4161/hv.7.9.15996
20. Austrian R, Douglas RM, Schiffman G, Coetzee AM, Koornhof HJ, Hayden-Smith S, Reid RD. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976; 89:184-94; PMID:14433
21. Evers SMAA, Ament AJHA, Colombo GL, Konradsen HB, Reinert RR, Sauerland D, Wittrup-Jensen K, Loiseau C, Fedson DS. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis 2007; 26:531-40; PMID:17570001; http://dx.doi.org/10.1007/s10096-007-0327-z
22. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59:1102-6; PMID:20814406
23. Sherwin RL, Gray S, Alexander N, McGovern P, Graepel J, Pride MW, et al. Distribution of PCV13-serotype Streptococcus pneumoniae in adults aged ≥ 50 years presenting to select US hospitals with radiographically-confirmed community-onset pneumonia (abs). ID Week, San Diego, October 17-21, 2012.
24. Hak E, Grobbee DE, Sanders EAM, Verheij TJM, Bolkenbaas M, Huijts SM, Gruber WC, Tansey S, McDonough A, Thoma B, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66:378-83; PMID:18990781
25. Musher DM. Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults? Clin Infect Dis 2012; 55:265-7; PMID:22495544; http://dx.doi.org/10.1093/cid/cis364